INTERFERONS AND EYE DISEASES
https://doi.org/10.15372/SSMJ20190318
Abstract
The review contains an analysis of the medical use of interferons – a group of signaling protein molecules that have antiviral, antitumor, and immunomodulatory activity – in ophthalmic practice. Interferons have a wide spectrum of action, including antiviral, immunomodulatory, antitumor and other types of activity. This provides a great potential for interferon use in ophthalmology, both in combination and as a first-line therapy for conjunctival papillomatosis, squamous cell neoplasia, conjunctival melanoma, keratitis caused by the herpes simplex virus, uveitis, geographical choriopathy, cystic and diabetic macular edemas, etc. There are considered mechanism of action, dosing regimens, side effects of using interferons and such their solutions as use of newly discovered interferon lambda and interferon pegylation. In contrast to the ubiquitous expression of the IFN-α receptor, IFN-λ receptor is determined mainly in the epithelial cells of the mucous membranes and skin keratinocytes, which provides a more targeted effect of the drugs. Modifying the properties of biologically active substances by combining them with low molecular weight carriers, for example, polyethylene glycol molecules (PEG), leads to a decrease in the therapeutic dose of the drug and an increase in the selectivity of its action due to changes in pharmacokinetic and pharmacodynamic parameters.
About the Authors
N. A. Kikhtenko
«Vision center “Doctor Linz”», Ltd.
Russian Federation
Russian Federation
Kikhtenko Nikolay Andreevich – ophthalmologist
630005, Novosibirsk, Krylov str., 63
P. G. Madonov
Novosibirsk State Medical University of Minzdrav of Russia
Russian Federation
Russian Federation
Madonov Pavel Gennad’evich – doctor of medical sciences, head of the Department of pharmacology, clinical pharmacology and evidence-based medicine
630091, Novosibirsk, Krasny av., 52
References
1. Артамонов А.В., Бекарев А.А., Балданов Н.В., Киншт Д.Н., Мадонов П.Г., Мирошников П.Н., Дыгай А.М., Данилец М.Г., Лигачева А.А., Масная Н.В., Трофимова Е.С., Шерстобоев Е.Ю., Шитикова О.Г. Противоэнтеровирусное и иммуностимулирующее средство. Пат. 2554761 РФ; Опубл. 27.06.2015.
2. Артамонов А.В., Бекарев А.А., Дыгай А.М., Жданов В.В., Киншт Д.Н., Мадонов П.Г., Шерстобоев Е.Ю. Пегилированный интерферон лямбда, обладающий высокой биодоступностью при пероральном применении, и способ его получения. Пат. 2678332 РФ; Опубл. 28.01.2019.
3. Денисов Л.А., Шолохов И.В. Открытие интерферона и его клиническое применение // Инфекц. болезни. 2017. (1). 23–31.
4. Ершов Ф.И., Наровлянский А.Н. Теоретические и прикладные аспекты системы интерферонов: к 60-летию открытия интерферонов // Вопр. вирусологии. 2018. 63. (1). 10–18.
5. Ершов Ф.И., Киселев О.И. Интерфероны и их индукторы (от молекул до лекарств). М.: ГЭОТАРМедиа, 2005.
6. Киншт Д.Н., Мадонов П.Г., Ластовецкий А.Г., Китанина К.Ю., Удут В.В. Технология электронно-лучевого синтеза как перспективное направление в разработке иммобилизированных интерферонов для перорального применения (обзор литературы) // Вестн. нов. мед. технологий. 2017. (3). 211–225.
7. Чурин А.А., Шерстобоев Е.Ю., Киншт Д.Н., Тартынова Т.С., Мадонов П.Г. Доклиническое исследование токсичности пероральной формы пегилированного интерферона α-2b при его длительном введении // Сиб. науч. мед. журн. 2018. 38. (1). 17–21.
8. Ashkenazy N., Karp C.L., Wang G., Acosta C.M., Galor A. Immunosuppression as a possible risk factor for interferon nonresponse in ocular surface squamous neoplasia // Cornea. 2017. 36. (4). 506–510.
9. Bielefeld P., Devilliers H., Deschasse C., Saadoun D., Se`ve P., Muselier A., Creuzot-Garcher C., Besancenot J.F., Bron A.M. Potential of pegylated interferon alpha-2a in Behc ̧et uveitis: a report of five cases // Ocul. Immunol. Inflamm. 2016. 24. (5). 599–602.
10. Blasi M.A., Tiberti A.C., Valente P., Laguardia M., Sammarco M.G., Balestrazzi A., Larocca L.M., Balestrazzi E. Intralesional interferon-α for conjunctival mucosa-associated lymphoid tissue lymphoma: long-term results // Ophthalmology. 2012. 119. (3). 494–500.
11. Bodaghi B., Gendron G., Wechsler B. Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients // Br. J. Ophthalmol. 2007. 91. (3). 335–339.
12. Butler N.J., Suhler E.B., Rosenbaum J.T. Interferon alpha 2b in the treatment of uveitic cystoid macular edema // Ocul. Immunol. Inflamm. 2012. 20. (2). 86–90.
13. Cellini M., Balducci N., Strobbe E., Campos E.C. Subtenon injection of natural leukocyte interferon a-2a in diabetic macular edema: a case report // BMC Ophthalmol. 2013. 13. 63.
14. Chalkia A.K., Spandidos D.A., Detorakis E.T. Viral involvement in the pathogenesis and clinical features of ophthalmic pterygium (Review) // Int. J. Mol. Med. 2013. 32. (3). 539–543.
15. Chaugule S.S., Park J., Finger P.T. Topical chemotherapy for giant ocular surface squamous neoplasia of the conjunctiva and cornea: is surgery necessary? // Indian J. Opthalmol. 2018. 66. (1). 55–60.
16. Costa M.B., Picon P.D., Sander G.B., Cuni H.N., Silva C.V., Meireles R.P., Góes A.C.M.A., Batoreu N.M., Maia M.L.S., Albuquerque E.M., Matos D.C.S., Saura P.L. Pharmacokinetics comparison of two pegylated interferon alfa formulations in healthy volunteers // BMC Pharmacol. Toxicol. 2018. 19. (1). 1–1.
17. Deuter C.M., Gelisken F., Stubiger N. Successful treatment of chronic pseudophakic macular edema (Irvine-Gass syndrome) with interferon alpha: a report of three cases // Ocul. Immunol. Inflamm. 2011. 19. (3). 216–218.
18. Deuter C.M., Kotter I., Gunaydin I., Stubinger N., Doycheva D., Gierhut M. Efficacy and tolerability of interferon alpha treatment in patients with chronic cystoid macular oedema due to non-infectious uveitis // Br. J. Ophthalmol. 2009. 93. 906–913.
19. Erdem U., Kerimoglu H., Gundogan F.C., Dagli S. Treatment of Mooren’s ulcer with topical administration of interferon alfa 2a // Ophthalmology. 2007. 114. (3). 446–449.
20. Foster G.R. Pegylated interferons for the treatment of chronic hepatitis C: pharmacological and clinical differences between peginterferon-alpha-2a and peginterferon-alpha-2b // Drugs. 2010. 70. (2). 147–165.
21. Ganapathy P.S., Plesec T., Singh A.D. Conjunctival squamous papilloma refractory to interferon α-2b in a patient on systemic immunosuppression (tacrolimus) // Am. J. Ophthalmol. Case Rep. 2017. 6. 1–3.
22. Garip A., Schaumberger M.M., Wolf A., Herold T.R., Miller C.V., Klingenstein A., SchebitzWalter, Hintschich C.R. Evaluation of a short-term topical interferon a-2b treatment for histologically proven melanoma and primary acquired melanosis with atypia // Orbit. 2016. 35. (1). 29–34.
23. Gillies M.C., Garrett S.K., Shina S.M., Morlet N., Taylor H.R. Topical interferon alpha 2b for corneal haze after excimer laser photorefractive keratectomy. The Melbourne Excimer Laser Group // J. Cataract Refract. Surg. 1996. 22. (7). 891–900.
24. Gupta P.C., Ram J. Comparative evaluation of tacrolimus versus interferon alpha-2b eye drops in the treatment of vernal keratoconjunctivitis: a randomized, double-masked study // Cornea. 2017. 36. (6). 675–678.
25. Holds J., Buchanan A., Hanson R. Intralesional interferon-α for the treatment of bilateral conjunctival mucosa-associated lymphoid tissue lymphoma // Pediatr. Blood Cancer. 2012. 59. (1). 176–178.
26. Hruska M., Wang X., Chan P., Ahmad A., Freeman J., Horga M.A., Hillson J., Kansra V., Lopez-Talavera J.C. Derivation of Phase 3 dosing for peginterferon lambda-1a in chronic hepatitis C, Part 2: Exposure-response analyses for efficacy and safety variables // J. Clin. Pharmacol. 2015. 55. (1). 73–80.
27. Huerva V., Manques I. Treatment of conjunctival squamous neoplasias with interferon alpha 2ab // J. Fr. Ophthalmol. 2008. 31. (3). 317–325.
28. Ikeda T., Sato K., Tokuyama T. Interferon alfa therapy against metastatic iris tumor of renal cell carcinoma // Arch. Ophthalmol. 2000. 118. (6). 846– 847.
29. Invernizzi A., Iannaccone F., Marchi S., Mastrofilippo V., Coassin M., Fontana L., Salvarani C., McCluskey P., Cimino L. Interferon alpha-2a for the treatment of post-infectious uveitis secondary to presumed intraocular tuberculosis // Ocul. Immunol. Inflamm. 2018. 22. 1–8.
30. Kaliki S., Singh S., Iram S., Tripuraneni D. Recombinant interferon alpha 2b for ocular surface squamous neoplasia: an efficient and cost-effective treatment modality in Asian Indian patients // Indian J. Ophthalmol. 2016. 64. (10). 702–709.
31. Kikuchi I., Kase S., Ishijima K., Ishida S. Longterm follow-up of conjunctival melanoma treated with topical interferon alpha-2b eye drops as adjunctive therapy following surgical resection // Graefes Arch. Clin. Exp. Ophthalmol. 2017. 255. (11). 2271–2276.
32. Kusumesh R., Ambastha A., Sinha B., Kumar R. Topical Interferon a-2b as a single therapy for primary ocular surface squamous neoplasia // Asia Pac. J. Ophthalmol. (Phila). 2015. 4. (5). 279–282.
33. Lazear H.M., Schoggins J.W., Diamond M.S. Shared and distinct functions of type i and type III interferons // Immunity. 2019. 50. (4). 907–923.
34. Leibovitch I., Loewenstein A., Alster Y., Rosenblatt I., Lazar M., Yassur Y., Rubinstein A. Interferon alpha-2a for proliferative diabetic retinopathy after complete laser panretinal photocoagulation treatment // Ophthalmic Surg. Lasers Imaging. 2004. 35. (1). 16–22.
35. Lewczuk N., Zdebik A., Bogusławska J. Interferon alpha 2a and 2b in ophthalmology: A review // J. Interferon Cytokine Res. 2019. [Epub ahead of print]. doi: 10.1089/jir.2018.0125.
36. Maleki A., Aghaei H., Lee S. Topical interferon alpha 2b in the treatment of refractory pseudophakic cystoid macular edema // Am. J. Ophthalmol. Case Rep. 2018. 10. 203–205.
37. Mercado C.L., Pole C., Wong J., Batlle J.F., Roque F., Shaikh N., Murillo J.C., Galor A., Karp C.L. Surgical versus medical treatment for ocular surface squamous neoplasia: A quality of life comparison // Ocul. Surf. 2019. 17. (1). 60–63.
38. Minkovitz J.B., Pepose J.S. Topical interferon alpha-2a treatment of herpes simplex keratitis resistant to multiple antiviral medications in an immunosuppressed patient // Cornea. 1995. 14. (3). 326–330.
39. Moon C.S., Nanji A.A., Galor A., McCollister K.E., Karp C.L. Surgical versus medical treatment of ocular surface squamous neoplasia: A cost comparison // Ophthalmology. 2016. 123. (3). 497–504.
40. Oray M., Onal S., Uludag G., Akbay A.K., Tugal-Tutkun I. Interferon alpha for the treatment of cystoid macular edema associated with presumed ocular tuberculosis // J. Ocul. Pharmacol. Ther. 2017. 33. (4). 304–312.
41. Pagan Carrasco S., Arranz Maestro D. Topical interferon alpha-2B topic as the first therapeutic option in a clinical case of conjunctival intraepithelial neoplasia // Arch. Soc. Esp. Oftalmol. 2017. 92. (9). 442–446.
42. Patel H., Jeang L.J., Shah A., Espana E.M., Margo C.E. Widespread ocular surface squamous neoplasia treated with topical interferon alpha-2b // Ocul. Oncol. Pathol. 2018. 4. (5). 298–303.
43. Plskova J., Greiner K., Forrester J.V. Interferonalpha as an effective treatment for noninfectious posterior uveitis and panuveitis // Am. J. Ophthalmol. 2007. 144. (1). 55–61.
44. Qian Z., Fardeau C., Cardoso J.N., Jellab B., Fan X., LeHoang P. Effect of interferon a2a in cystoid macular edema due to intraocular infection // Eur. J. Ophthalmol. 2015. 25. (5). 431–436.
45. Singh M., Gautam N., Gupta A., Kaur M. Interferon alfa-2bin the management of recurrent conjunctival papillomatosis // Indian J. Ophthalmol. 2016. 64. (10). 778–780.
46. Singh M., Gautam N., Kaur M. Role of topical interferon alpha-2b in «mitomycin-C-resistant» ocular surface squamous neoplasia: our preliminary findings // Int. Opthalmol. 2019. 39. (2). 295–301.
47. Tan J.C., Tat L.T., Coroneo M.T. Treatment of partial limbal stem cell deficiency with topical interferon a-2b and retinoic acid // Br. J. Ophthalmol. 2016. 100. (7). 944–948.
48. Viani G.A., Fendi L.I. Adjuvant treatment or primary topical monotherapy for ocular surface squamous neoplasia: a systematic review // Arq. Bras. Oftalmol. 2017. 80. (2). 131–136.
49. Wilhelmus K.R. Antiviral treatment and other therapeutic interventions for herpes simplex virus epithelial keratitis // Cochrane Database Syst. Rev. 2015. 1. ID CD002898.
50. Yalcinbayir O., Yucel A.A., Kaderli B., Gelisken O. Subconjunctival interferon a-2a application in a case with serpiginous choroidopathy // Retin. Cases Brief Rep. 2009. 3. (2). 214–217.
51. Zarei-Ghanavati M., Mousavi E., Nabavi A., Latifi G., Mehrjardi H.Z., Mohebbi M., Ghassemi H., Mirzaie F., Zare M.A. Changes in vivo confocal microscopic findings of ocular surface squamous neoplasia during treatment with topical interferon alfa-2b // Ocul. Surf. 2018. 16. (2). 235–241.
Review
For citations:
Kikhtenko N.A., Madonov P.G. INTERFERONS AND EYE DISEASES. Сибирский научный медицинский журнал. 2019;39(3):117-125. (In Russ.) https://doi.org/10.15372/SSMJ20190318
Views:
262
Email this article 